Free tool
FAERS Monitor: Dexilant
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022287 or its brand name (Dexilant, Dexlansoprazole). Reports on generic versions are filed under their own applications.
Reports
41,708
Serious
33,723
81% of reports
Hospitalization
7,317
Death reported
3,737
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- chronic kidney disease16,102
- acute kidney injury7,811
- renal failure6,722
- end stage renal disease4,888
- renal injury4,339
- drug ineffective2,627
- fatigue2,442
- off label use2,345
- nausea2,244
- tubulointerstitial nephritis2,191
- diarrhoea2,006
- headache1,972
- pain1,965
- death1,887
- dyspnoea1,652
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 114 |
| 2011 | 375 |
| 2012 | 710 |
| 2013 | 707 |
| 2014 | 989 |
| 2015 | 1,641 |
| 2016 | 2,105 |
| 2017 | 1,672 |
| 2018 | 13,439 |
| 2019 | 7,819 |
| 2020 | 2,724 |
| 2021 | 2,416 |
| 2022 | 1,915 |
| 2023 | 1,556 |
| 2024 | 1,362 |
| 2025 | 1,292 |
| 2026 | 869 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,012,451 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| end stage renal diseaseSignal | 4,888 | 184.2 | 178.5 | 652,603 |
| chronic kidney diseaseSignal | 16,102 | 135.3 | 133.4 | 1,698,139 |
| renal injurySignal | 4,339 | 86.1 | 83.4 | 311,908 |
| tubulointerstitial nephritisSignal | 2,191 | 66.6 | 63.8 | 125,122 |
| acute kidney injurySignal | 7,811 | 27.1 | 26.5 | 187,441 |
| renal failureSignal | 6,722 | 26.8 | 26.2 | 159,708 |
| pain | 1,965 | 1.6 | 1.5 | 472 |
| headache | 1,972 | 1.6 | 1.5 | 441 |
| fatigue | 2,442 | 1.6 | 1.5 | 543 |
| diarrhoea | 2,006 | 1.6 | 1.5 | 425 |
| dyspnoea | 1,652 | 1.5 | 1.4 | 257 |
| nausea | 2,244 | 1.4 | 1.4 | 301 |
| off label use | 2,345 | 1.4 | 1.3 | 223 |
| death | 1,887 | 1.1 | 1.1 | 19 |
| drug ineffective | 2,627 | 1.0 | 1.0 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.